HIGH IMPACT PUBLICATIONS

Dr. Ming Hai-Wang, Professor in the Department of Biomedical Sciences, and his team’s recent publication, "Efficacy of Anti-RON Antibody Zt/g4–Drug Maytansinoid Conjugation (Anti-RON ADC) as a Novel Therapeutics for Targeted Colorectal Cancer Therapy," was published in the December 1, 2014 edition of the journal, Clinical Cancer Research. (Impact Factor 8.193)... READ ARTICLE

Dr. Wei Wang, Research Assistant Professor and Dr. Ruiwen Zhang, Professor, and their team identified a new anticancer agent that targets the cancer-causing gene MDM2, which is linked to poor response to treatment in breast cancer patients. The study, The Pyrido indole MDM2 Inhibitor SP-141 Exerts Potent Therapeutic Effects in Breast Cancer Models, indicates that SP-141 is a novel targeted therapeutic agent that may especially benefit patients with advanced breast cancer. The article was accepted for publishing in the journal, Nature Communications (Impact Factor 10.742)... READ ARTICLE

Dr. Ruiwen Zhang, Professor in the Department of Pharmaceutical Sciences, and his team identified a new class of MDM2 inhibitor called SP141, which may be further developed as a therapy for pancreatic cancer. The study, Identification of a New Class of MDM2 Inhibitor that Inhibits Growth of Orthotopic Pancreatic Tumors in Mice, was just accepted for publishing in the journal Gastroenterology (Impact Factor 13.926). READ ARTICLE

New Grants and Awards - Fall 2015

AWARDS AND HONORS

Congratulations toDr. Thomas J. Abbruscato

Dr. Thomas Abbruscato has been appointed as chairperson of the Drug Discovery for the Nervous System Study Section, Center for Scientific Review, NIH, for the term beginning summer 2015 and ending in summer 2016.